Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in a Phase 2/3 clinical trial (NCT01760005). Despite these results, the data collected will prove useful for identifying biomarkers and improving understanding of early-onset Alzheimer’s and the more common form of the disease that develops after the age of 65 (late-onset), researchers said. “Although the drugs we evaluated were not successful, the trial will move us forward in understanding Alzheimer’s,” Randall J. Bateman, MD, the study’s principal investigator and a neurology professor, said in a news story.
Solanezumab and Gantenerumab Fail to Slow Memory Loss or Cognitive Decline in Early-onset Alzheimer’s, Study Finds
aging Alzheimers alzheimers awareness Alzheimers Disease alzheimers prevention alzheimers risk alzheimers treatment blood brain brain health chakra cognition cognitive decline cognitive impairment cognitive problems Dementia diagnosis diet dietary habits early detection exercise food gender health health benefits inflammation lifestyle lifestyle medicine meditation Memory mental health mindfulness neurodegeneration neuroscience neuroscientists nutrition preventative care prevention research risk sleep treatment wellness women yoga